Exhibit (a)(14)

Dear Perrigo Colleagues,

Earlier today we announced actions that will strengthen our ability to deliver future sustainable growth. These changes will enable us to further improve our global operations and efficiency to enhance our position as a leading global healthcare company. In summary, these actions will involve a number of strategic steps:

• Implementing a number of operational and cost efficiency measures;

• Refining our business portfolio, including commencing a sale process for the U.S. Vitamins, Minerals and Supplements (VMS) business;

• Undertaking initiatives to capture the benefits of the company’s global platform, consolidating and optimizing its global supply chain, procurement and research and development functions in Ireland; and

• Investing in our business by authorizing a $2 billion share repurchase plan.

As a result of these actions, I am confident that Perrigo will emerge from the Mylan tender offer period as a stronger company. Now is the time to take the next step in our strategy to leverage the powerful global platform we have built.

Additionally, we announced that John Hendrickson, formerly Executive Vice President, Global Operations and Supply Chain, will be promoted to the position of President, effective immediately, reporting to me. With 26 years of experience at Perrigo, John has a deep understanding of our business, proven management skills and a strong, competitive drive that will ensure Perrigo continues to deliver at the highest levels. Please join me in congratulating John.

These changes further strengthen Perrigo’s focus on organic growth strategies, while ensuring efficient global capabilities in quality, research and development, information technology and services, human resources and finance. We are confident that these actions will maintain the momentum we have built over the last decade in leveraging our innovation, and market leadership in the global healthcare markets in which we compete. While some of these actions will impact a portion of our team, what will not be impacted is our dedication to respecting people, operating with integrity, and never compromising the quality of what we do.

Additional details on today’s announcement will be available later today on Inside Perrigo. Your business segment or function leadership will provide more information in the weeks ahead.

Your ongoing support and commitment are essential as we continue in building an even stronger and more efficient company, committed to providing Quality Affordable Healthcare Products® to our customers around the globe. Through the initiatives announced today we are making a great company - with an outstanding track record of value creation and compelling prospects for continued growth - even better.

Joe Papa

Chairman & CEO

Forward-Looking Statements

Certain statements in this communication are forward-looking statements. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and

projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including future actions that may be taken by Mylan in furtherance of its unsolicited offer; the timing, amount and cost of share repurchases; and the ability to execute and achieve the desired benefits of announced initiatives. These and other important factors, including those discussed under “Risk Factors” in the Perrigo Company’s Form 10-K for the year ended June 27, 2015, as well as the Company’s subsequent filings with the SEC, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this communication are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Additional Information and Where to Find it

This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. In response to the exchange offer commenced by Mylan N.V., Perrigo has filed a solicitation/recommendation statement on Schedule 14D-9 with the Securities and Exchange Commission (“SEC”). Security holders are urged to read the solicitation/recommendation statement and other relevant materials if and when they become available because they will contain important information. The solicitation/recommendation statement and other SEC filings made by Perrigo may be obtained (when available) without charge at the SEC’s website at www.sec.gov and at the investor relations section of the Perrigo website at perrigo.investorroom.com. Shareholders may also obtain copies of the information by contacting Mackenzie Partners, Inc. at 212-929-5500 or 800-322-2885 Toll-Free in North America or by email at PRGO@mackenziepartners.com.

Irish Takeover Rules

The directors of Perrigo accept responsibility for the information contained in this communication. To the best of the knowledge and belief of the directors of Perrigo (who have taken all reasonable care to ensure such is the case), the information contained in this communication is in accordance with the facts and does not omit anything likely to affect the import of such information